Short Interest in Silexion Therapeutics Corp (NASDAQ:SLXN) Drops By 89.3%

Silexion Therapeutics Corp (NASDAQ:SLXN) saw a large decrease in short interest during the month of June. As of June 15th, there was short interest totaling 16,557 shares, a decrease of 89.3% from the May 31st total of 154,973 shares. Based on an average trading volume of 233,740 shares, the days-to-cover ratio is presently 0.1 days. Currently, 4.1% of the company’s shares are short sold.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Silexion Therapeutics in a research report on Monday, June 15th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold”.

Silexion Therapeutics Stock Up 0.7%

Shares of NASDAQ SLXN traded up $0.02 during midday trading on Friday, hitting $2.75. The stock had a trading volume of 32,999 shares, compared to its average volume of 207,813. The company has a market capitalization of $1.16 million, a price-to-earnings ratio of -0.03 and a beta of -0.32. Silexion Therapeutics has a 1-year low of $2.31 and a 1-year high of $223.60. The company has a fifty day moving average price of $5.20 and a 200 day moving average price of $13.74.

Silexion Therapeutics (NASDAQ:SLXN) last posted its earnings results on Friday, May 15th. The company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($12.90) by $12.05. On average, research analysts forecast that Silexion Therapeutics will post -45.5 EPS for the current year.

Silexion Therapeutics Company Profile

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.